Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy
Crossref DOI link: https://doi.org/10.1245/s10434-017-5898-z
Published Online: 2017-05-30
Published Print: 2017-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Petruolo, Oriana A.
Pilewskie, Melissa
Patil, Sujata
Barrio, Andrea V.
Stempel, Michelle
Wen, Hannah Y.
Morrow, Monica
Funding for this research was provided by:
NIH/NCI Cancer Center Support Grant (P30 CA008748)
License valid from 2017-05-30